Clifford A. Hudis, MD, chief of the breast cancer medicine service at Memorial Sloan-Kettering Cancer Center, has been elected president of the American Society of Clinical Oncology (ASCO). He will be introduced as president-elect during the organization's annual meeting in June and will serve a 1-year term as president beginning in June 2013.

Hudis will work with ASCO's 30,000 member physicians to improve access to cancer care, as well as the effectiveness and affordability of care.

A graduate of the Medical College of Pennsylvania, Hudis focuses his research on preventing and treating breast cancer recurrence after surgery. He works on clinical and translational studies to develop more effective hormone therapies, less toxic chemotherapy drugs, and new targeted agents. [Photo courtesy of Memorial Sloan-Kettering Cancer Center.]

Pasi A. Jänne, MD, PhD, and Kwok-Kin Wong, MD, have been named scientific codirectors of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute (DFCI).

Jänne directs DFCI's Translational Research Laboratory. His work combines laboratory-based experiments, translational research, and clinical trials of novel therapeutic agents in patients with lung cancer. He also studies mechanisms of acquired resistance to targeted therapies and strategies to effectively treat drug-resistant cancers. [Photo courtesy of Dana-Farber Cancer Institute/Sam Ogden.]

Wong is a medical oncologist at DFCI's Lowe Center for Thoracic Oncology. A recognized leader in the development of mouse models of cancer, Wong studies the origins of cancer and the molecular determinants of treatment responses. He is particularly interested in genetic alterations in lung cancers and testing novel targeted lung cancer therapies in vivo. [Photo courtesy of Dana-Farber Cancer Institute/Sam Ogden.]

For more news on cancer research, visit Cancer Discovery online at